Cargando…
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis
PROBLEM: New drugs for infectious diseases often need to be evaluated in low-resource settings. While people working in such settings often provide high-quality care and perform operational research activities, they generally have less experience in conducting clinical trials designed for drug appro...
Autores principales: | Tupasi, Thelma, Gupta, Rajesh, Danilovits, Manfred, Cirule, Andra, Sanchez-Garavito, Epifanio, Xiao, Heping, Cabrera-Rivero, Jose L, Vargas-Vasquez, Dante E, Gao, Mengqiu, Awad, Mohamed, Gentry, Leesa M, Geiter, Lawrence J, Wells, Charles D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Health Organization
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750433/ https://www.ncbi.nlm.nih.gov/pubmed/26908964 http://dx.doi.org/10.2471/BLT.15.154997 |
Ejemplares similares
-
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013) -
Multidrug-Resistant TB in the Philippines: Authors' Reply
por: Tupasi, Thelma
Publicado: (2006) -
Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility
por: Lunte, Kaspars, et al.
Publicado: (2015) -
Multidrug-resistant Tuberculosis Management in Resource-limited Settings
por: Nathanson, Eva, et al.
Publicado: (2006) -
Timely delivery of laboratory efficiency information, Part I: Developing an interactive turnaround time dashboard at a high-volume laboratory
por: Cassim, Naseem, et al.
Publicado: (2020)